rise in serum cortisol was observed on theﬁrst day of AC2993 treatment, similar tothat seen with GLP-1 (37), the assessmenton day 28 revealed no such rise in anystudy patient. There were no clinicallyrelevant effects of AC2993 on other clin-ical laboratory analytes, blood pressure,or heart rate. In conclusion, these data demon- strate for the ﬁrst time in a randomized,triple-blinded trial that AC2993 adminis-tered BID or TID for 28 days in patientsFineman and Associates DIABETES CARE,VOLUME 26, NUMBER 8, A UGUST 2003 2375Downloaded from http://diabetesjournals.org/care/article-pdf/26/8/2370/660914/dc08030023 0.pdf by guest on 17 January 2024